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INTRODUCTION
While the incidence and the mortality of gastric cancer in
the Western world have decreased, gastric cancer is the most
common form, and the second leading cause of death in Korea.
With most cases being diagnosed at an advanced stage, the
prognosis for this disease is extremely poor (1). Although
localized advanced gastric cancer can be cured by surgery,
metastatic or recurrent gastric cancer remains incurable, and
these patients have a median survival of 6 to 9 months. The
efficacy of palliative chemotherapy is now widely accepted
based on many clinical trials (2-4), although no single or
combination chemotherapeutic regimen has been accepted
as the standard treatment. 
The 5-Fluorouracil (5-FU) is one of the most effective
agents in advanced gastric cancer commonly used with cis-
platin or anthracycline. Especially, 5-FU and cisplatin (CF)
combination chemotherapy has been widely accepted as a
standard treatment with a significant higher response rate
and prolongation of progression free survival (PFS) compared
to single 5-FU or combination with adrimamycin/mitomycin
(5-7). However, the meaningful prolongation of overall sur-
vival (OS) is dim yet. To overcome these problems, many
studies have been reported and are under progress. 
Taxanes (docetaxel and paclitaxel) are a class of anticancer
agents that bind to microtubules and induce hyperstabiliza-
tion, causing cell cycle arrest and apoptosis (8, 9). They have
demonstrated promising activity in gastric cancer, and are
currently being tested in many clinical trials as a combina-
tion regimen (10-13). In particular, the contribution of doc-
etaxel in advanced gastric cancer has been reported in large
scale of clinical trials. Ajani et al. showed the docetaxel addi-
tion to CF (DCF) produced a higher response rate than DC
(14). Based on this result, V325 study has been going on to
compare of DCF in experimental arm to CF in reference arm.
It showed that DCF arm improved the time-to-progression
(TTP), response rate, but also OS than CF arm (15). How-
ever, hematological toxicity was significant, with grade 3 or
4 neutropenia being over 80%. In view of palliative aim in
advanced gastric cancer, these toxicities, sometimes related
with fatal infection, could be attenuated the benefit of che-
motherapy. 
Therefore, we conducted the study to show the efficacy
and decrease the toxicity of taxane-based chemotherapy. The
toxicities between paclitaxel and docetaxel are somewhat
different, especially in neurotoxicity and neutropenia. In ovar-
ian cancer, two taxanes showed an equivalent therapeutic
efficacy, but neutropenia was more common with docetaxel-
586
Junyl Hwang, Sang-Hee Cho, 
Hyun Jeong Shim, Se-Ryeon Lee,
Jae Sook Ahn, Duk-Hwan Yang, 
Yeo-Kyeoung Kim, Je-Jung Lee, 
Hyeoung-Joon Kim, and Ik-Joo Chung
Department of Internal Medicine, Division of
Hemato/Oncology, Chonnam National University 
Medical School, Gwangju, Korea
Address for correspondence
Ik-Joo Chung, M.D.
Department of Internal Medicine, Chonnam National
University Hwasun Hospital, 160 Ilsim-ri, Hwasun-eup,
Hwasun-gun 519-809, Korea
Tel : +82.61-379-7632, Fax : +82.61-379-7628
E-mail : ijchung@chonnam.ac.kr
J Korean Med Sci 2008; 23: 586-91
ISSN 1011-8934
DOI: 10.3346/jkms.2008.23.4.586
Copyright � The Korean Academy
of Medical Sciences
Phase II Study of Paclitaxel, Cisplatin, and 5-Fluorouracil Combination
Chemotherapy in Patients with Advanced Gastric Cancer
This phase II study evaluated the efficacy and safety of combination chemothera-
py with paclitaxel, cisplatin, and 5-fluorouracil (5-FU) in advanced gastric cancer.
Patients with histologically confirmed gastric adenocarcinoma were eligible for the
study. Paclitaxel (175 mg/m
2) and cisplatin (75 mg/m
2) were given as a 1-hr intra-
venous infusion on day 1, followed by 5-FU (750 mg/m
2) as a 24-hr continuous infu-
sion for 5 days. This cycle was repeated every 3 weeks. Forty-five eligible patients
(median age, 56 yr) were treated in this way. Of the 41 patients in whom efficacy
was evaluable, an objective response rate (ORR) was seen in 51.2% (95% CI,
0.35-0.67), a complete response in two, and a partial response in 19 patients. The
median progression free survival was 6.9 months (95% CI, 5.86-7.94 months), and
the median overall survival was 12.7 months (95% CI, 9.9-15.5). The main hema-
tological toxicity was neutropenia and greater than grade 3 neutropenia was observ-
ed in twelve patients (54%). Febrile neutropenia developed in three patients (6.8%).
The major non-hematological toxicities were asthenia and peripheral neuropathy,
but most of patients showed grade 1 or 2. In conclusion, combination chemothera-
py with paclitaxel, cisplatin, and 5-FU is a promising regimen, and was well tolerat-
ed in patients with advanced gastric cancer.  
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based regimen, up to 3 times than paclitaxel-based regimen
(16, 17). Also, Park et al. (18) compared the combination of
palictaxel plus 5-FU (PF) with docetaxel plus 5-FU (DF) in
gastric cancer. There were no significance differences in ther-
apeutic efficacy. In DF group, dose reduction was more com-
mon than in PF group and grade 3 or 4 neutropenia was
slightly frequent in DF (21%) than PF (18%). There were
four and eight patients with febrile neutropenia in the PF
and DF, respectively. Taken together, docetaxel could be
replaced by paclitaxel to reduce the neutropenia without
diminish the efficacy. Thus, we performed this study to eval-
uate the efficacy and safety of combination chemotherapy
with paclitaxel addition to CF in advanced gastric cancer as
a three-week regimen.
MATERIALS AND METHODS
Patients
Patients had histologically confirmed metastatic gastric
adenocarcinoma. Eligibility criteria included at least one mea-
surable lesion; Eastern Cooperative Oncology Group perfor-
mance status ≤2; age >18 yr, life expectancy ≥3 months,
no other malignancy; and adequate hematological, renal,
and hepatic function (white blood cell count ≥3,000/μ L,
granulocytes ≥1,500/μ L, platelets ≥100,000/μ L, total biliru-
bin <1.3 mg/dL, and creatinine clearance >60 mL/min). No
prior palliative chemotherapy was permitted in patients with
advanced disease. Adjuvant chemotherapy was allowed if
>12 months had elapsed between the end of therapy and
registration. 
Exclusion criteria were as follows: preexisting neurotoxic-
ity greater than or equal to grade 2 of the National Cancer
Institute Common Toxicity Criteria (NCI-CTC, version 2.0),
concurrent cancer, central nervous system metastasis, active
infection, other serious underlying medical conditions that
would impair the ability of the patient to receive the planned
treatment, or inadequate calorie and fluid intake. Partici-
pants gave written informed consent before they entered the
study, which was approved by the Chonnam National Uni-
versity Hospital ethical committee. 
Treatment schedule and dose modification
Paclitaxel (175 mg/m2) and cisplatin (75 mg/m2) were
given as a 1-hr intravenous infusion on day 1, followed by 5-
FU (750 mg/m2) as a 24-hr continuous infusion for 5 days.
Cycles were repeated every 3 weeks. Thirty minutes prior to
the paclitaxel infusion, each patient received 20 mg dexam-
ethasone, 50 mg ranitidine, and 5 mg chlorpheniramine
maleate intravenously to prevent hypersensitivity reactions.
After prehydration with at least 1 L normal saline, the cal-
culated dose of paclitaxel, diluted in 300 mL normal saline,
was infused over 1 hr. The calculated dose of cisplatin, dilut-
ed in 500 mL normal saline, was then administered over 1 hr,
followed by posthydration with 3 L normal saline over 24 hr.
Soon after finishing the cisplatin infusion, 5-FU was infused
continuously for 5 days. Ondansetron (8 mg, i.v) was routine-
ly given. Patients received further cycles of chemotherapy
only when the absolute neutrophil count was ≥1,000/μ L
and platelets were ≥150,000/μ L. Toxicity was graded accord-
ing to NCI-CTC version 2.0. Dose modifications were deter-
mined by hematological or non-hematological toxicities.
The cisplatin dose was reduced to 75% of the original dose
in subsequent cycles if one of the following occurred: grade
3 neutropenia with infection, grade 4 neutropenia, grade 3
thrombocytopenia with bleeding that required platelet trans-
fusion and greater than grade 3 sensory neurotoxicity, or grade
2 or greater nephrotoxicity. In case of subsequent toxicities
after these dose reductions, the paclitaxel dose was reduced
to 75% of the original dose. In cases of asthenia above grade
3, treatment was postponed for 1 week and restarted when
the patient had recovered to below grade 2. If the toxicity
did not improve to below grade 1 after 4 weeks, the patients
was removed from the study. Also, the paclitaxel dose was
reduced to 75% of the original dose if grade 2 sensory neu-
rotoxicity was sustained subsequent 2 cycles despite the med-
ication such as amitryptiline. For patients with grade 3 diar-
rhea that lasted for more than 7 days despite the administra-
tion of loperamide or mucositis grade 3 lasting for more than
5 days or grade 4 mucositis, a 25% reduction in the daily
dose of 5-FU was required. To avoid the delay of chemother-
apy, G-CSF was given if the absolute neutrophil count was
lower than 1,000/μ L seven to ten days after chemotherapy.
Patients showing disease regression or stable disease received
additional cycles of chemotherapy, up to a maximum of nine
cycles, unless they experienced disease progression or unac-
ceptable toxicity, or if the patients refused or the physician
decided against further treatment. 
Evaluation
The antitumor activity was evaluated according to the
World Health Organization (WHO) criteria. Computed
tomography (CT) scans of measurable lesions were carried
out within 4 weeks before the start of the treatment and were
repeated after every three cycles. Complete response (CR)
was defined as the complete disappearance of all evaluable
disease, persisting for >4 weeks. Partial response (PR) was
defined as a ≥50% reduction in the sum of the products of
the largest perpendicular diameters in all measurable lesions
for ≥4 weeks, without evidence of progression or the devel-
opment of new lesions. Progressive disease (PD) was defined
as an increase in a previous lesion by >25%, or the develop-
ment of any new lesion, and stable disease (SD) as any change
in a previous lesion that did not fit into either the PR or PD
categories. The patients were consulted in assessing the res-588 J. Hwang, S.-H. Cho, H.J. Shim, et al.
ponse if they had early disease progression or had received at
least two cycles of treatment. 
Data analysis
The primary endpoint was ORR, and secondary endpoints
were PFS, OS and toxicity. This study was conducted using
a Simon two-stage design. The optimal number of patients
was determined assuming a target level of interest, p1=0.6,
and a lower activity level, p0=0.4. Initially we planned to
enroll 34 patients in first stage. If 18 or more responses were
observed, we planned to continue second stage for a total of 39
evaluable patients. This design provides for a probability of
≤0.05 of accepting drugs worse than p0, and a probability
of ≤0.20 of rejecting drugs better than p1. If we assume
the dropout rate to be 15%, the total number of enrolled
patients will be 45. All enrolled patients were included in
the intent-to-treat analysis. The Kaplan-Meier method was
used in all survival analysis. The Statistics Package for the
Social Sciences (SPSS) program for Windows (Version 13.0)
was applied for analysis. 
RESULTS
Patient characteristics
Forty-five patients were initially enrolled in this study. Of
these, four patients were dropped out; one had another pri-
mary tumor (esophageal cancer), two were lost to follow-up
after one cycle of chemotherapy, and one did not want fur-
ther chemotherapy after one cycle. The median age of patients
was 56 yr, with a range of 21 to 75 yr (Table 1). Thirty pati-
ents were male (68%) and 14 were female (32%); most pati-
ents were in good general condition with a performance sta-
tus of 0 or 1 (82%). All patients had histologically confirm-
ed adenocarcinoma. Twenty-seven patients (61%) had recur-
rent disease after operation with or without adjuvant chemo-
therapy and seventeen patients (39%) had no prior treatment
in metastatic gastric cancer. The median follow-up duration
was 12.8 months (95% CI, 6.2-24.8)
Chemotherapy delivery
The median number of treatment cycles was six, with a
range from three to nine cycles. The number of patients
receiving more than six cycles was 33 (80%). The median
duration of treatment for all patients was 147 days, with a
range of 46 to 245 days. All patients received more than
three cycles of chemotherapy, and forty one patients were
able to evaluate their response. The total number of cycles
delivered was 269. The number of patients who were receiv-
ed at least 1 dose reduction and at least 1 cycle delay were
13 (29.5%) and 7 (15.9%), respectively. The target doses
for paclitaxel, cisplatin, and 5-FU were 58.3, 25, and 1,250
mg/m2/week, respectively, and the achieved doses for pacli-
taxel, cisplatin, and 5-FU were 52.3 (89.7%), 22.3 (89.2%),
Characteristics Number %
Number of enrolled patients  45
Number of eligible patients 44 98
Sex
Male/Female 30/14 68/32
Median age (range) 56 (21-75)
ECOG performance status
01 4 3 2
12 2 5 0
28 1 8
Histology
Adenocarcinoma 42 95
Signet ring cell carcinoma 2 5
Disease status 
Recurrent 27 61
Surgery only 14 32
Surgery with adjuvant chemotherapy 13 29
- Doxifluridine  6
- FP 3
- FAM 4
Metastatic without prior treatment 17 39
Sites of metastasis
Lymph node 26 59
Peritoneum 18 41
Liver 12 27
Ovary 4 9
Table 1. Patient characteristics
ECOG, Eastern Cooperative Oncology Group; FP, 5-FU and cisplatin;
FAM, 5-FU, adriamycin and mitomycin-C. 
All patients
(n=41)
Recurrent
(n=26)
Metastatic
(n=15)
Age
≤60 (n=26) >60 (n=15)
CR 2 (5%) 2 (8%) 0 0 2 (13%)
PR 19 (46%) 11 (42%) 8 (53%) 12 (46%) 7 (47%)
CR+PR 21 (51%) 13 (50%) 8 (53%) 12 (46%)  9 (60%)
SD 15 (37%) 9 (35%) 6 (41%) 10 (39%) 5 (34%)
PD 5 (12%) 4 (15%) 1 (6%) 4 (15%) 1 (6%)
Table 2. Tumor responses  
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.Paclitaxel, Cisplatin and 5-FU in Advanced Gastric Cancer 589
and 1,131.2 mg/m2/week (90.5%), respectively.
Efficacy 
Initially, 34 patients were treated as scheduled. Of these
patients, one patient showed CR, 18 patients showed PR, 12
patients showed SD and 3 patients showed PD. Therefore,
we advanced this study up to 45 patients. The best respons-
es are shown in Table 2. Two patients achieved CR (4.9%;
95% CI, 1-16) and 19 patients PR (46.3%; 95% CI, 31-63).
The ORR was 51.2% (95% CI, 35-67) with a median res-
ponse duration of 23 weeks. The responses of the 26 patients
who had recurrent disease were 2 CR, 11 PR, 9 SD, and 4
PD, and the responses who had no prior treatment in metastat-
ic disease were 8 PR, 6 SD, and 1 PD. No statistically signifi-
cant difference was observed between the two groups. Among
12 patients who had carcinomatosis peritonei with ascites,
four showed marked reduction of ascites after chemothera-
py, and three did not need further paracentesis (SD). Two
patients were treated with palliative surgery after the sixth
and ninth cycles, and they had no evidence of disease until
data analysis. 
Survival outcome
Of the 44 patients, four (9.1%) remained alive at a medi-
an follow-up of 12.8 months. The median progression-free
survival was 6.9 months (95% CI, 5.86-7.94). The median
OS was 12.7 months (95% CI, 9.9-15.5) and the 1-yr OS
rate was 62.5% (Fig. 1).
Toxicity
Chemotherapy-related toxicity is summarized in Table 3.
The main hematological toxicity was neutropenia. Grade 3
or 4 neutropenia was observed in 67 cycles (25%) and 54%
of patients. Greater than grade 3 thrombocytopenia develop-
ed in only two patients (5%). Eighteen patients (41%) receiv-
ed growth factor before starting the next cycle of chemother-
apy to prevent delayed treatment. Febrile neutropenia devel-
oped in three patients (7.3%) and all of them recovered after
treatment; two patients recovered after a short course of antibi-
otic treatment and one patient needed intensive care treat-
ment. Grade 1 or 2 peripheral sensory neuropathy was observ-
ed in 32 patients (72%), and greater than grade 3 peripher-
al sensory neuropathy occurred in two patients (5%). The
major non-hematological toxicity was asthenia, which spon-
taneously resolved after 1 or 2 weeks of rest. No treatment-
related mortality occurred. 
Number of patients (%, n=44)
0
Toxicities
1234
Number of cycles (%, n=269)
01 2 3 4
Hematologic
Leukopenia 9 (20) 8 (18) 17 (39) 8 (18) 2 (5) 136 (51)  60 (22) 49 (18) 22 (8) 2 (1)
Neutropenia 8 (18) 4 (10) 8 (18) 12 (27) 12 (27) 122 (45)  41 (15) 39 (15) 40 (15) 27 (10)
Anemia 7 (16) 9 (20) 24 (54) 4 (10) 0 128 (47)  83 (31) 54 (20) 4 (2) 0
Thrombocytopenia 39 (88) 0 3 (7) 2 (5) 0 251 (93)  13 (5) 4 (2) 1 (0) 0
Non-hematologic
Asthenia 5 (11) 16 (37) 18 (41) 5 (11) 0 115 (60) 109 (41) 36 (13) 9 (3) 0
Myalgia 25 (57) 14 (32) 5 (11) 0 0 162 (60) 79 (29) 28 (11) 0 0
Nausea 17 (39) 18 (41) 8 (18) 1 (2) 0 162 (60) 82 (30) 23 (9) 2 (1) 0
Vomiting 16 (36) 14 (32) 11 (25) 3 (7) 0 190 (71) 60 (22) 19 (7) 0 0
Anorexia 19 (43) 18 (41) 7 (16) 0 0 150 (56) 94 (35) 23 (8) 2 (1) 0
Mucositis 18 (41) 13 (23) 10 (23) 3 (7) 0 186 (69) 61 (23) 14 (5) 8 (3) 0
Diarrhea 31 (70) 10 (23) 2 (5) 1 (2) 0 219 (81) 39 (15) 7 (3) 4 (1) 0
Peripheral neuropathy 10 (23) 15 (34) 17 (38) 2 (5) 0 121 (45) 94 (35) 52 (19) 2 (1) 0
Table 3. Toxicities 
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Fig. 1. Survival curves of progression-free survival (PFS) and over-
all survival (OS).
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DISCUSSION
Taxanes have been used widely as single agents in the treat-
ment of gastric cancer. Paclitaxel is well tolerated and demon-
strates response rates in the 17-23% range (19). Docetaxel
has also been found to be active in advanced gastric cancer,
with ORRs between 17 and 29% (20, 21). Both taxanes are
known for their synergistic effect with cisplatin in vivo and
in vitro, especially when paclitaxel precedes platinum admin-
istration (22). Based on these results, taxanes have been wide-
ly used in combination with cisplatin, with or without 5-FU.
Docetaxel has been widely used in advanced gastric cancer
and a randomized phase III trial of DCF versus CF in meta-
static gastric adenocarcinoma was reported (15). The doses
and schedule of the DCF arm were docetaxel 75 mg/m2 on
day 1, cisplatin 75 mg/m2 on day 1, and 5-FU 750 mg/m2/
day as continuous infusion on days 1-5, repeated every 3
weeks. The overall response of DCF group showed 37% (CF
group: 25%) and the duration of TTP and OS were signifi-
cantly longer in DCF group than in CF group. Although OS
was slightly increased in DCF group (9.2 months) compared
with in CF group (8.6 months), a considerable benefit was
observed with the 2-yr survival rate of 18% for DCF and
9% for CF. Despite these results, the DCF regimen showed
a high rate of toxicities. The rate of grade 3 or 4 neutropenia
and febrile neutropenia were 82.3 and 29%, respectively. In
the view of palliative aim for chemotherapy in advanced gas-
tric cancer, although docetaxel-based chemotherapy is effec-
tive in disease control, it is thought to be too toxic. Therefore,
triple combination chemotherapy would be better in disease
control and prolongation of survival, but further study is need-
ed to reduce the toxicity. As mentioned above, paclitaxel had
less myelosuppressive effect than docetaxel (16, 17).
Previously, the combination chemotherapy with paclitax-
el, cisplatin, and 5-FU was reported by Kim et al. (11) with
at the following doses: paclitaxel 175 mg/m2 on day 1, 5-
FU 750 mg/m2 by 24-hr continuous infusion on days 1-5,
and cisplatin 20 mg/m2 on days 1-5, every 28 days and it
showed promising report as triple chemotherapy with a high
response rate of 51%, similar with our results. However, the
response duration (17 weeks) and the median survival time
about 6 months (26 weeks) seems disappointing. To make
up for this point, we enhanced the dose intensity of chemo-
therapy. Compare with the previously used dosage, the doses
of paclitaxel and 5-FU in our study were increased by 25%
because the schedule was repeated every 3 weeks. Following
the treatment, the response rate was similar, but the response
duration and PFS were prolonged. Especially the PFS in this
study was comparable to the OS previously reported. The
PFS would be a more reasonable parameter in the evalua-
tion of the chemotherapy because the OS could be affected
by 2nd-line chemotherapy. Actually, 24 (58.6%) patients
received the 2nd-line chemotherapy such as oral fluorouri-
dine, irinotecan or oxaliplatin and it may be related with the
gap between PFS and OS. Nonetheless, the prolongation of
the response duration and the PFS were meaningful. It also
demonstrated effectiveness in controlling carcinomatosis peri-
tonei, frequently seen in advanced gastric cancer. In terms
of toxicity, this regimen was fairly well tolerated. Greater
than grade 3 neutropenia developed in 25% of total cycles
and 54% of patients. Taken into consideration about 86%
of patients who developed greater than grade 3 neutropenia
in DCF chemotherapy (14), the frequency of neutropenia
was decreased. The most common non-hematological toxic-
ity was asthenia. Greater than grade 3 asthenia was devel-
oped in five patients, but these patients were able to receive
further chemotherapy after resting about one week. Sensory
neuropathy was seen in 55% of cycles, but most of these were
grade 1 or 2. Neuropathy seemed to be associated with dose
reduction, and no severe sensory neurotoxicity, including
motor weakness, was observed. 
In conclusion, combination chemotherapy with paclitax-
el, cisplatin, and 5-FU at the dose used in this study is an
effective regimen, and its safety may be useful for palliative
treatment in patients with advanced gastric cancer. For more
convenient regimen with reduced toxicity, further clinical
trials on combination with oral fluorouracil are needed. 
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